164 results about "Cord blood" patented technology

The invention relates to the technical field of NK cell culture, and discloses a serum-free medium for NK cells from umbilical cord blood after cryopreservation and a culture method thereof.The medium comprises a coating solution, an induction medium and an amplification medium; wherein the coating liquid is prepared from an anti-CD16 monoclonal antibody and DPBS (diphenylphosphonic acid); the induction culture medium comprises a basic culture medium, a human-derived platelet lysate and cell factors IL-15, IL-18 and IL-21; the amplification culture medium comprises a basic culture medium, a human-derived platelet lysate and IL-2. The culture method comprises the following steps: obtaining mononuclear cells from fresh umbilical cord blood, and then cryopreserving and resuscitating; and carrying out multiplication culture on the recovered umbilical cord blood mononuclear cells by using the serum-free culture medium. According to the NK cell culture medium, the NK cells with high purity, high killing activity and high cytotoxic activity can be obtained without autoserum culture.

The invention discloses a method for culturing CIK (Cytokine-Induced Killer) cells and application thereof. The method comprises the following steps: recovering cord blood, mixing and centrifuging the recovered cord blood and a buffer solution, re-suspending and precipitating, centrifuging again to obtain cord blood mononuclear cells, inoculating the cord blood mononuclear cells into an activation culture medium, and culturing to obtain the CIK cells, the buffer solution contains L-proline, human recombinant DNA enzyme and angelica polysaccharide. According to the method, the mononuclear cells can be separated from the umbilical cord blood preserved by liquid nitrogen, the utilization rate of the umbilical cord blood which can only be discarded due to insufficient cells is increased, the traditional lymphocyte separation process is optimized, the recovery rate of the mononuclear cells is increased, and the cost is reduced. The method provided by the invention can be used for culturing dozens to ten billions of CIK cells from a small amount of cryopreserved cord blood, and has huge advantages in the field of CIK cell culture and application.

The invention relates to a leukocyte extract extraction and purification method, and belongs to the field of biology. Specifically, animal umbilical cord blood is selected as a raw material, a leukocyte extract is obtained through a series of extraction and purification steps, and polypeptide shown in SEQ ID NO.1-2 is obtained through further separation; the leukocyte extract and polypeptide prepared by the invention have remarkable antioxidant and anti-wrinkle effects and can be used for preparing medicines or cosmetics with special effects, and the application prospect of the leukocyte extract is expanded.

The invention provides an anti-hair loss and hair growth composition and application thereof, the composition comprises exosome freeze-dried powder, collagen freeze-dried powder and a traditional Chinese medicine extract, the exosome freeze-dried powder is obtained by extracting exosome from umbilical cord or umbilical cord blood and freeze-drying; the traditional Chinese medicine extract is selected from at least two of a lucid ganoderma extract, a ginseng extract, a honeysuckle flower extract and a polygonum multiflorum extract. The preparation formed by the hair loss prevention and hair growth composition can promote the generation of hair follicle cells, and stimulate hair follicles to enter a growth period while repairing the hair follicles, so that the growth of new hair is promoted, the problem of hair loss is remarkably improved, and the hair is densified and blackened.

The invention relates to a composition containing a leukocyte extract and a white tomato extract and application of the composition in cosmetics, and belongs to the technical field of cosmetics and biology. Specifically, animal umbilical cord blood is selected as a raw material, and the leukocyte extract is obtained through the steps of extraction and purification; meanwhile, white tomato polypeptide is extracted, and further separation is performed to obtain the polypeptide as shown in SEQ ID NO.1-2; the leukocyte extract and the white tomato polypeptide have good safety, have remarkable antioxidant and whitening effects through synergism, can be safely used in the field of cosmetics, and expand the application prospects of the leukocyte extract and the white tomato polypeptide.

The utility model provides dialysis and separation equipment for umbilical cord blood. The dialysis and separation equipment comprises a first separation plate, a second separation plate, a bag and dredging units, wherein the first separation plate and the second separation plate are composed of filter membranes and impermeable membranes, the bag is made of flexible materials, and the dredging units are arranged on the two sides of the bag and used for squeezing. The filter membrane and the impermeable membrane are tightly combined to form an outlet, and the bag is divided into three cavities which are respectively used for treating umbilical cord blood and controlling liquid flow through a catheter and a valve. The dredging unit periodically extrudes the bag through the extrusion part and the control part, so that the filter membrane is prevented from being blocked. The equipment can effectively separate blood components through the matching of the filter membranes with different pore diameters and functions, and realizes a reliable, effective, simple and economical umbilical cord blood dialysis and separation mode.

The invention provides a preparation method and application of super memory NK cells. The method comprises the following steps: S1, separating from peripheral blood or umbilical cord blood to obtain mononuclear cells; s2, culturing the mononuclear cells by using an NK activation culture medium; s3, separating CD3-CD56 + cells from the cultured mononuclear cells, so as to obtain purified NK (Natural Killer) cells; and S4, stimulating the NK cells by using a memory factor to induce the NK cells into memory-like NK cells, and culturing the memory-like NK cells by using an amplification culture medium to prepare the super-memory NK cells. Before the NK sorting kit is used for sorting and purifying the cells, the NK activation culture medium containing IL-2, IL-15 and IL-18 is used for conducting induction culture on the mononuclear cells, the NK cells can be activated, the total cell amount is greatly increased, the number of the NK cells obtained through follow-up sorting is increased, the problems that the number of the NK cells purified through PBMC in the early stage is small, and the culture difficulty is large are solved, and the cell quality is improved. The total cell quantity of the finally cultured super memory NK cells is increased.

The invention discloses a small-molecule compound and application thereof in in-vitro amplification of hematopoietic stem cells and / or progenitor cells. The structural general formula of the small-molecule compound is as shown in formula (I). The series of compounds disclosed by the invention can be used in the medical field of related diseases taking hematopoietic stem cell transplantation as a treatment method, including in-vitro amplification culture of hematopoietic stem cells and progenitor cells from umbilical cord blood, bone marrow and mobilized peripheral blood and culture, maintenance and amplification of genetically modified hematopoietic stem and progenitor cells; meanwhile, the invention is suitable for application of downstream derived cell products generated by hematopoietic stem cell differentiation, including red blood cells, blood platelets, T cells, B cells and NK cells, in drugs for treating related diseases. # imgabs0 #

The invention provides an immortalized NK cell line SZ093 derived from healthy human umbilical cord blood as well as a preparation method and application of the immortalized NK cell line SZ093. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood is preserved in Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, and has high killing capacity on tumor cells.

The invention relates to the technical field of cosmetics, and discloses an umbilical cord blood moisturizing essence composition, an umbilical cord blood moisturizing essence as well as a preparation method and application of the umbilical cord blood moisturizing essence. The composition contains a hydrolyzed placenta extract, placenta protein, an umbilical cord extract, a guava fruit extract, a radix gentianae extract, decapeptide-4, nonapeptide-1, a lactobacillus fermentation product and a yeast fermentation product filtrate. The umbilical cord blood moisturizing essence prepared from the composition has multiple effects of moisturizing, repairing and resisting aging, and is mild, safe, excellent in stability and high in active ingredient retention rate.

The present invention relates to a method for culturing natural killer cells derived from umbilical cord blood using transformed T cells. The method for culturing natural killer cells using transformed T cells according to the present invention can efficiently propagate and produce natural killer cells from a small amount of original cells. In addition, the method can also improve the cell killing ability of natural killer cells. Therefore, the method for culturing natural killer cells using transformed T cells according to the present invention can be usefully used to commercialize cell therapeutic agents. In addition, the natural killer cells produced by the culturing method of the present invention can be usefully used as cell therapeutic agents.

The invention relates to the technical field of medicines, in particular to application of combined use of NK cells and a GD2 antibody in preparation of a medicine for treating neuroblastoma. The NK cell and the GD2 antibody are jointly used to prepare a medicine for treating neuroblastoma. In-vivo and in-vitro experiments find that the umbilical cord blood NK cell combined with the GD2 antibody can significantly enhance the tumor killing ability and inhibit the growth of neuroblastoma cells, provides a new therapeutic medication scheme for the treatment of neuroblastoma, and has a good application prospect in the prevention and treatment of neuroblastoma.

The application belongs to the technical field of cell culture, and particularly relates to umbilical cord blood-derived endothelial cell culture additives, an endothelial cell culture method and application. The umbilical cord blood-derived endothelial cell culture additives comprise activated platelet-rich plasma and at least one of miR-132 and miR-193b-3p high expression and miR-155 low expression exosomes. The application further provides an endothelial cell culture medium comprising the umbilical cord blood-derived endothelial cell culture additives, and the culture medium can significantly improve the growth state of HUVEC cells and effectively reduce or even avoid the vacuolization phenomenon in the culture process.

The invention discloses application of an umbilical cord blood exosome in preparation of a medicine for treating ophthalmic diseases caused by aging. It is found that the umbilical cord blood exosome can improve the biological characteristics of senescent trabecular meshwork cells, relieve the senescence characteristics of the trabecular meshwork cells, improve the DNA damage repair capacity of the cells, promote proliferation of the trabecular meshwork cells and effectively maintain the stability of cell nucleuses, and then growth and division of the cells are supported. The umbilical cord blood exosome shows a remarkable anti-aging effect in treatment of ophthalmic diseases caused by aging, can effectively improve the biological function of trabecular meshwork cells, slow down the aging process and promote cell proliferation and repair, and has wide application potential.

The present invention provides a cell population and a method for obtaining the same. The cell population of the present invention is obtained by culturing mononuclear cells derived from bone marrow, umbilical cord blood or peripheral blood in a culture medium containing four or less factors selected from stem cell factor, interleukin 6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and serum.

The invention belongs to the field of biomedicine, and particularly relates to a detection method, an evaluation method and application of umbilical cord blood-derived natural killer cells. The detection method disclosed by the invention is used for carrying out related detection and data analysis on the natural killer cells from umbilical cord blood, is high in pertinence and can be used as a detection method for delivering the NK cells from a warehouse. According to the evaluation method, the relationship between the NK function related protein and the cell killing ability is determined, the killing ability of the NK cells is judged by detecting functional protein indexes CD3, NKG2A, CD56, CD16, NKP46 and CD107A of the natural killer cells and calculating NK scores of samples based on detection results, the sensitivity and specificity are high, and the method can be used for evaluating the killing ability of the NK cells.

The invention belongs to the technical field of biological medicine, and particularly relates to a frozen umbilical cord blood NK cell amplification method which comprises the following steps: S1, umbilical cord blood NK cell separation; s2, performing serum-free culture; s3, performing dynamic amplification; and S4, performing cryopreservation and resuscitation verification. According to the invention, after unfreezing, a culture medium containing a TGF-beta inhibitor (Galunissertib) is firstly used for pretreatment for 24 hours, so that an inhibitory signal is blocked, and the survival rate is increased. The dynamic amplification adopts three-stage metabolism regulation: stage 1: in a low-oxygen environment, using a culture medium containing SCF + FLT3L + IL-7 to promote activation of NK cells in a stationary period; stage 2: under a normal oxygen condition, switching to IL-12 + IL-18 + IL-21, and adding an antioxidant NAC to reduce ROS accumulation; and stage 3: pulse-type stimulation: adding CD16 cross-linked magnetic beads every 48 hours to enhance cytotoxicity.

The utility model relates to the technical field of biological experiment instruments, in particular to a hanging accessory used in the separation process of umbilical cord blood hematopoietic stem cells, which is mainly used for being connected with a grid at the top of a biological safety cabinet and comprises a fixed end connected with the grid at the top of the biological safety cabinet, and a hook used for being connected with a blood bag is arranged below the fixed end. The fixing end comprises a clamping ring, a torsional spring clamping opening capable of being clamped into a grid is formed in the clamping ring, a limiting sliding groove is formed in the inner side of the clamping ring, and a limiting rod capable of moving up and down along the inner wall of the clamping ring is slidably connected into the limiting sliding groove. A reset spring capable of resetting the limiting rod upwards is arranged between the bottom of the limiting sliding groove and the limiting rod. The technical problems that in the prior art, a blood bag is connected with a grid in a biological safety cabinet through a paper clip, then the blood bag is hung, shaking is large, the blood bag is prone to falling off, a sample possibly needs to be centrifuged many times, and the motility rate of the sample is affected are solved.

The invention belongs to the field of biological detection, and particularly relates to a blood treating fluid and a method for performing karyotype analysis by using the treating fluid. The treating fluid prepared by the invention comprises a treating fluid A and a treating fluid B. The treating fluid can be used for treating umbilical cord blood of a fetus at the early pregnancy stage, so that the interference of red blood cells can be reduced, and rapid proliferation of lymphocytes can be induced. The umbilical cord blood treated by the treatment liquid is subjected to chromosome karyotype analysis, can be refined into number abnormality or structure abnormality typing, and has important significance for clinical prenatal diagnosis.

The present disclosure discloses a method for isolating osteoprogenitors like mesenchymal stem cells (MSCs) from clotted bone marrow and culturing with a platelet lysate obtained from a combination of discarded umbilical cord blood and maternal blood platelet-rich plasma (instead of non-human animal origin serum) and differentiating those MSCs into osteoblasts under sterile conditions for further therapeutic applications. Particularly, the present disclosure relates to a method for expansion of osteoblasts to make cell therapy products with a fixed cell dose, which are characterized and later cryopreserved for future use through its cell culture process. Further, the present disclosure relates to identifying specific gene expression from MSCs to osteoblast formation, an in-vitro differentiation process that replicates the in-vivo bone remodelling system.

The invention relates to the field of biomedicine, and discloses application of EPTMPA in hematopoietic stem cell in-vitro amplification culture. The invention identifies a brand-new novel small molecule compound EPTMPA capable of remarkably promoting in-vitro expansion and in-vivo transplantation of hematopoietic stem cells and hematopoietic progenitor cells of umbilical cord blood, and the novel small molecule compound EPTMPA can remarkably promote in-vitro expansion of CD34 + hematopoietic stem cells and hematopoietic progenitor cells and maintain the stem property and differentiation potential. EPTMPA is a new discovery and new way for in-vitro amplification of hematopoietic stem cells, but needs more studies to understand the action mechanism, targeting genes and proteins of the hematopoietic stem cells and the regulation effect on self-renewal and differentiation balance of the stem cells. The researches are of great significance to clinical application and product development in the future.

The application belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of umbilical cord blood plasma-derived extracellular vesicles and related bioactive molecules thereof in treatment of Alzheimer's disease. Specifically, the application isolates extracellular vesicles (UCBP-sEVs) from umbilical cord blood plasma, which has the effect of improving Alzheimer's disease. Further research finds that high enrichment of miR-16-2-3p therein is a key molecule for mediating treatment of Alzheimer's disease. miR-16-2-3p targets and inhibits expression of ROCK2, reduces phosphorylation level of TFEB and promotes nuclear translocation of the same, activates microglial autophagy-lysosome pathway, and thus promotes phagocytosis and degradation of intracerebral beta amyloid, and therefore has good practical application value.

Provided herein are populations of ex vivo expanded umbilical cord blood-derived regulatory T cells. Also provided are methods of making and using the same.

Described herein are novel methods for fractionating and isolating platelets, platelet- and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin, and methods of using the isolated platelets, platelet and extracellular vesicle-derived growth factors, exosomes, globulins, fibrinogen and albumin for regenerating tissue in a subject, treating fibrinogenemia or a clotting deficiency in a subject, treating ischemia and hypoxia, treating dry-eye syndrome, an orthopedic disorder, or a dental disorder in a subject. Also described herein are growth media for culturing mammalian (e.g., human) cells.

The invention provides a preparation method and application of an anti-IL-11 antibody modified Treg cell, and belongs to the technical field of genetic engineering.The preparation method of the anti-IL-11 antibody modified Treg cell comprises the steps that after the Treg cell and umbilical cord blood pluripotent stem cells are co-cultured, the Treg cell is separated and recycled, an anti-IL-11 antibody is adopted for modification, and the anti-IL-11 antibody modified Treg cell is obtained; the nucleotide sequence of the anti-IL-11 antibody is as shown in SEQ ID NO. 2 in the sequence table. In the co-culture process, stem cells are used for providing an immune microenvironment, promoting Treg cell amplification and enhancing the inhibition ability of Treg cells, and obtaining the specific recognition ability of pancreas islet beta cell antigens, so that autoimmune attacks are inhibited more accurately; the nucleotide sequences of the heavy chain and the light chain of the anti-IL-11 antibody are optimized, and the anti-IL-11 antibody has higher efficacy in treatment of diabetic mice.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD73 positive NK cells of umbilical cord blood from different starting sources and application of the CD73 positive NK cells to treatment of Alzheimer's disease. The CD73 + NK cells differentiated from different initial cell types (CD34 positive cells, CD3 negative / CD56 positive cells and CD56 negative cells) of umbilical cord blood are studied, it is found that all the initial cell types of umbilical cord blood sources can be differentiated into the CD73 + NK cells, 34 +-73-NK cells show a higher growth rate, 56-73-NK cells show higher cytotoxicity, and the CD73 + NK cells can be differentiated into the CD73 + NK cells. And the overall effect of the 56-73-NK cell is superior to that of the 34 < + >-73-NK cell. Further research shows that the CD73 + NK can inhibit activation of STZ injection mouse hippocampal microglia and astroglia, so that the neuroinflammation of the hippocampal is reduced, and a new solution is expected to be provided for treatment of AD.

The invention provides a stem cell exosome composition for repairing skin and hair follicle injury as well as a preparation method and application thereof, and belongs to the technical field of cell repair. The invention provides a stem cell exosome composition for repairing skin and hair follicle injury. The stem cell exosome composition comprises the following components in parts by weight: 30-50 parts of umbilical cord mesenchymal stem cell exosome, 15-25 parts of a ginseng extract, 15-25 parts of lotus placenta, 10-20 parts of a saffron crocus extract, 10-20 parts of tea bran and 10-20 parts of a mulberry leaf extract. The traditional Chinese medicine extract and the umbilical cord blood mesenchymal stem cell exosome are mixed and then immediately applied to damaged skin or scalp, the mixture is applied 3-5 times every day, one treatment course comprises 7 days, and after 1-3 treatment courses, the damaged skin is remarkably healed, the scalp oil phenomenon is remarkably relieved, and hair of hair follicles is remarkably increased.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+ cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

A method for alleviating fatigue, comprising administering to a patient in need thereof an effective amount of a human umbilical cord blood composition, which comprises hematopoietic progenitor cells, monocytes, lymphocytes, granulocytes, or a combination thereof.

To provide a population of cord blood-derived regulatory T cells expanded ex vivo. To provide a method for producing a population of cord blood-derived regulatory T cells expanded ex vivo, and a method for using the same.SOLUTION: Provided is a population of human Treg cells comprising at least about 1 * 10 8 human Treg cells, wherein (i) ≥ 60% are CD4 + CD25 + and (ii) ≤ 10% are CD4 - CD8 +, wherein said human Treg cells are immunosuppressive.SELECTED DRAWING: Figure 1